Publications

Wang et al. validated the effectiveness and safety of UPA in this real-world study of Chinese PsA patients. UPA demonstrated comparable effectiveness to secukinumab (SEC) in psoriatic lesion improvement while showing comparable joint symptom relief compared with adalimumab (ADA), coupled with a favourable safety profile.

UPA offers notable convenience in clinical practice, positioning it as an excellent therapeutic option for PsA management. SEC maintained its established advantages in both cutaneous and articular outcomes, while ADA exhibited particularly robust effects on joint pain alleviation alongside its articular benefits. These findings provide valuable evidence for personalised treatment selection in PsA care, emphasising the importance of considering dominant disease manifestations and administration preferences when choosing among these targeted therapies.